Tazocin

Tazocin belongs to a large group of drugs with antimicrobial and antiparasitic properties. This group includes a subgroup of antibiotics, among which is Tazocin.

Among the antibiotics there is a group of beta-lactam antibiotics, which includes a subgroup of penicillins. The drug Tazocin belongs to this penicillin subgroup.

Indications Tazocin

Indications for the use of the drug Tazocin for adult patients and children over twelve years of age are as follows:

1. The drug is indicated for use in the presence of moderate to severe infections caused by microorganisms that are sensitive to the active substances of the drug.

These infections include:

• infectious diseases of bacterial origin that affect the upper and lower respiratory tract; from pneumonia, the drug can be used only for diseases of moderate severity that are not caused by pepicilin-resistant beta-lactamase-producing strains of Haemophilus influenzae, as well as microorganisms that are sensitive to piperacillin and that produce beta-lactamase, which is an enzyme that destroys penicillin and its derivatives;
• infectious diseases of organs located in the abdominal cavity; these include manifestations of complicated appendicitis - an inflammatory process in the appendix of the small intestine, peritonitis - an inflammatory process in the peritoneum;
• infectious diseases of the skin, also affecting soft tissues, of uncomplicated and complicated nature; such problems include manifestations of cellulitis - a fibrous inflammatory process of the subcutaneous fat; various abscesses (abscesses); symptoms of infected trophic ulcers (which, for example, affect patients with a history of diabetic angiopathy - damage to the walls of blood vessels due to an increase in the concentration of sugar in the blood);
• infectious diseases of the organs located in the pelvis; these include infectious diseases of the urinary system, complicated or uncomplicated; diseases of a gynecological nature - which also include manifestations of endometritis and adnexitis that appear in the postpartum period;
• bacterial infectious diseases that manifest in patients with symptoms of neutropenia (a decrease in the number of neutrophils in the blood serum) - are used in combination with aminoglycosides;
• bacterial septicemia - certain forms of the disease, which is characterized by infection of human blood with bacteria;
• infectious lesions of the skeletal system, affecting the bones and joints of the patient;
• various diseases caused by mixed microorganisms of aerobic and anaerobic origin;
• therapy of conditions with a severe infectious and inflammatory nature, the causative agent of which has not yet been identified.

2. For pediatric patients from two to twelve years of age, the drug Tazocin is used as follows:

• for intra-abdominal infections (diseases of an infectious nature caused by microorganisms living in the gastrointestinal tract and penetrating into other cavities of the peritoneum);
• in infectious diseases that occur together with neutropenia (combination use of the drug Tazocin and aminoglycosides is recommended).

[ 1 ], [ 2 ], [ 3 ]

Release form

The following release form is typical for the medicine Tazocin:

The drug belongs to the group of solid dosage forms - it is produced in the form of lyophilized powder or porous mass, with the help of which a solution for infusions is prepared. The color of the powder varies from almost white to pure white shades.

The active ingredients of the medication are:

• piperacillin sodium - 2084.9 milligrams (the amount of piperacillin monohydrate is two thousand milligrams);
• tazobactam sodium - 268.3 milligrams (the amount of tazobactam is two hundred and fifty milligrams).

Auxiliary components include:

• sodium citrate dihydrate - 110.22 milligrams (in the amount of citric acid - seventy-two milligrams);
• disodium edetate dihydrate - half a milligram.

One bottle of the medicine Tazocin contains active ingredients:

• four grams of piperacillin and half a gram of tazobactam;
• or piperacillin sodium – 4169.9 milligrams and tazobactam sodium – 536.6 milligrams;
• or when converted to piperacillin monohydrate - four thousand milligrams and to tazobactam - five hundred milligrams.

One bottle of the medicine Tazocin includes the following excipients:

• sodium citrate dihydrate - 220.43 milligrams or, when converted to citric acid, one hundred forty-four milligrams;
• Disodium edetate dihydrate - one milligram.

It is possible to produce bottles of the medicine Tazocin, which contain the following active substances:

• piperacillin - two grams;
• tazobactam - two hundred and fifty milligrams.

Accordingly, the amount of auxiliary components when packaging in these bottles is reduced by half, compared to the above packaging.

The drug Tazocin is produced for the amount of active substances - two grams of piperacillin and two hundred and fifty milligrams of tazobactam:

• in bottles made of colorless glass (type I). The capacity of each bottle is thirty milliliters. The bottles are sealed with a stopper made of butyl rubber material. The stopper is rolled up on top with an aluminum cap, which has a gray plastic tear-off cap. The surface of the cap can be smooth or contain the engraved inscription "Wyeth".
• in a cardboard box containing twelve bottles, where a cardboard divider is installed between two rows of bottles.
• Additionally, the package contains instructions for using the drug.

The drug Tazocin is produced for the amount of active substances - four grams of piperacillin and five hundred milligrams of tazobactam:

• in bottles made of colorless glass (type I). The capacity of each bottle is seventy milliliters. The bottles are sealed with a stopper made of gray butyl rubber. The stopper is rolled up on top with an aluminum cap, which has a purple plastic tear-off cap. The surface of the cap can be smooth or contain the engraved inscription "Wyeth".
• in a cardboard box containing twelve bottles, where a cardboard divider is installed between two rows of bottles.
• Additionally, the package contains instructions for using the drug.

[ 4 ], [ 5 ], [ 6 ], [ 7 ], [ 8 ]

Pharmacodynamics

The pharmacodynamics of the drug Tazocin are as follows:

One of the active components of the drug - piperacillin monohydrate - is a semi-synthetic bactericidal antibiotic with a wide spectrum of action. This substance is active against many gram-positive and gram-negative aerobic and anaerobic microorganisms.

The properties of piperacillin include the ability to inhibit the synthesis of cell wall membranes in microorganisms.

Tazobactam is a sulfone derivative of trialomethylpenicillanic acid. The properties of tazobactam include the ability to powerfully inhibit numerous beta-lactamases (which include varieties of plasmid and chromosomal beta-lactamases). These beta-lactamases in many cases stimulate the resistance of the microorganism to drugs of the pericillin group and cephalosporin group (which include third-generation cephalosporins). Tazobactam, as a component of the drug Tazocin, enhances the antimicrobial effect of the drug and helps to expand the spectrum of action of piperacillin. This occurs due to the inclusion of tazobactam in many microorganisms that produce beta-lactamases, which are usually resistant to piperacillin and other beta-lactam antibiotics.

Summarizing the properties of Tazocin, it can be said that this combination drug has the characteristics of a broad-spectrum antibiotic and a drug that promotes the inhibition of beta-lactamases.

The drug Tazocin is active against gram-negative bacteria that develop only in the presence of oxygen. These include beta-lactamase-producing and beta-lactamase-non-producing strains of microorganisms. These include Escherichia coli, Citrobacter (including Citrobacter freundii, Citrobacter diversus), Klebsiella (including Klebsiella oxytoca, Klebsiella pneumoniae), Enterobacter (including Enterobacter cloacae, Enterobacter aerogenes), Proteus vulgaris, Proteus mirabilis, Providencia rettgery, Providencia stuartii, Plesiomonas shigelloides, Morganella morganii, Serratia spp. (including Serratia marcescens, Serratia liquifaciens), Salmonella, Shigella, Pseudomonas aeruginosa and other pseudomonads (including Pseudomonas cepacia and Pseudomonas fluorescens), Xanthamonas maltophilia, gonococcus, meningococcus, Moraxella spp. (including Branhamella catarrhalis), Acinetobacter spp., Haemophilus influenzae or Pfeiffer's bacillus, Haemophilus parainfluenzae, Pasteurella multocida, Yersinia, Campylobacter, Gardnerella vaginalis.

Also, in vitro, an increase in the effectiveness of the combined use of piperacillin and tazobactam with aminoglycosides against multidrug-resistant Pseudomonas aeruginosa was noted.

The drug Tazocin is active against gram-positive bacteria (microorganisms that can exist in the absence of oxygen), which produce or do not produce beta-lactamase. These include strains of the following microorganisms: streptococci (including pneumococci, streptococci pyrrolidonyl peptidase - group A streptococci, Streptococcus bovis - group D streptococci, Streptococcus agalactiae - group B streptococci, Sfreptococcus viridance - green streptococcus, group C and group G streptococci); enterococci (including faecal enterococcus, Enterococcus faechtm); staphylococci - Staphylococcus aureus, which is sensitive to methylcillin, saprophytic staphylococcus, epidermal staphylococcus (coagulase-negative forms); coryneform bacteria, listeria, Nocardia spp.

The drug Tazocin exhibits activity against anaerobic bacteria that produce and do not produce beta-lactamase. These include bacteroides (bacteroides bivius, bacteroides disiens, bacteroides capillosus, bacteroides melaninogenicus, bacteroides oralis, bacteroides fragilis, bacteroides vulgatus, bacteroides distasonis, bacteroides ovatus, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides asaccharolyticus), Peptosfreptococcus bacteria, Fusobacterium bacteria, Clostridium bacteria (including Clostridium difficile, Clostridium parfringens), Veilonella spp., Actynomyces spp.

[ 9 ], [ 10 ], [ 11 ], [ 12 ], [ 13 ]

Pharmacokinetics

The pharmacokinetics of the drug Tazocin are as follows:

Mechanism of drug distribution.

• The maximum amount of the drug in the blood serum is achieved immediately after the end of intravenous administration.
• Piperacillin administered with tazobactam has blood concentrations similar to those of piperacillin administered alone.
• Piperacillin and tazobactam are approximately 30 percent protein bound; the active substances do not interfere with each other in protein binding.
• The active ingredients - piperacillin and tazobactam - are widely distributed throughout the tissues and fluids of the body, including the intestinal epithelium, the gallbladder epithelium (as well as bile), the lung epithelium, the female genital organs (including the uterus, ovaries, fallopian tubes), and the skeletal system.
• The average level of active substance content in various tissues is from fifty to one hundred percent of the drug content in the blood serum.
• There is no information on the possibility of penetration of active components through the blood-brain barrier.

The mechanism of biotransformation of the active substances of the drug is as follows:

• During metabolism, piperacillin is transformed into a substance that has a lower level of activity, namely the desethyl derivative;
• During metabolism, tazobactam is transformed into an inactive metabolite substance.

The mechanism of elimination of the drug Tazocin from the body is as follows:

• The active substances – piperacillin and tazobactam – can be excreted by the kidneys; this process involves glomerular filtration and tubular secretion.
• Piperacillin can be excreted rapidly in the same form in which it was administered; sixty-eight percent of the amount ingested is found in the urine and is eliminated through it.
• Tazobactam and its metabolic products can be rapidly eliminated by renal function; eighty percent of the ingested amount of the substance is found in the same form in the urine, and the remainder of the tazobactam is in metabolic form.
• The elimination of piperacillin, tazobactam and desethylpiperacillin from the body is also possible through bile.
• If single and repeated administrations of the drug are prescribed to healthy patients, the half-life of the active substances from the blood serum varied from 0.7 to 1.2 hours; this process did not depend on the amount of the drug and the time of its administration into the body.
• If the creatinine clearance T1/2 is reduced, then the amount of time for the half-life of the drug to be eliminated from the body increases.

In case of renal dysfunction, the pharmacokinetics of the drug Tazocin is manifested as follows:

• As mentioned above, with a decrease in creatine clearance, the half-life of the active substances is extended.
• If creatine clearance decreases to less than twenty milliliters per minute, the half-life of the active substances increases - piperacillin by two times, and tazobactam by four times - compared to patients with normal renal function.
• During hemodialysis, thirty to fifty percent of piperacillin can be removed, as well as five percent of tazobactam in metabolic form.

If peritoneal dialysis is performed, six percent of piperacillin and twenty-one percent of tazobactam can be removed; eighteen percent of tazobactam is eliminated from the body in metabolic form.

In case of liver dysfunction, the pharmacokinetic characteristics of the drug are as follows:

• the half-life of active substances increases.
• there is no need to adjust the amounts of medication used.

[ 14 ], [ 15 ], [ 16 ], [ 17 ], [ 18 ]

Dosing and administration

There is a recommendation regarding a preliminary study of the patient's microflora: before using this medication, it is necessary to determine the presence or absence of sensitivity of the microorganisms that caused the disease to the active components of the drug.

The method of administration and dosage of the drug Tazocin are as follows:

The medicine Tazocin is intended for intravenous administration at a slow rate by jet stream during a time interval of at least three to five minutes. Or the medicine can be administered by drip during a time interval of twenty to thirty minutes.

The dosage of Tazocin and the duration of the course of therapy depend on the severity of the infectious disease, the location of the infectious focus, as well as the dynamic characteristics of the process of changing the clinical and bacteriological picture of the disease. The determination of the dosage of the drug is also influenced by the degree of sensitivity of microorganisms to the active substances of the drug.

The use of the drug for adults and children over twelve years of age with normal renal function is as follows:

• the daily dose of the drug is twelve grams of piperacillin and one and a half grams of tazobactan;
• the above-mentioned daily dose of active substances should be divided into several doses every six to eight hours;
• the daily amount of active components of the drug is determined based on the severity of the disease; the localization of the infection in the patient's body is also important;
• The maximum daily dose of the drug is eighteen grams of piperacillin and 2.25 grams of tazobactan; the daily dose of active substances should be divided into several doses for administration.

The method of using the drug Tazocin for children from two to twelve years old is as follows:

• in case of existing neutropenia in pediatric patients with normal renal function and a body weight of at least fifty kilograms - a single dose of Tazocin is ninety milligrams (eighty milligrams of piperacillin and ten milligrams of tazobactam) per one kilogram of the child's body weight;
• the above dose of the drug is administered every six hours together with the required amount of aminoglycosides;
• for pediatric patients weighing over fifty kilograms, the amount of the drug is equal to the dose of the drug for an adult, which is administered to the sick child together with aminoglycosides;
• in the presence of intra-abdominal infections in pediatric patients weighing up to forty kilograms and with normal renal function, the appropriate amount of the drug is one hundred milligrams of piperacillin and twelve and a half milligrams of tazobactam per kilogram;
• the above amount of the drug is administered to the patient every eight hours;
• Pediatric patients weighing over forty kilograms and with normal renal function take the same amount of the drug as adult patients.

Therapy with the drug is carried out for a period of five to fourteen days. It is necessary to take into account that the use of the drug should continue for at least forty-eight hours after the cessation of symptoms of the disease.

In case of impaired renal function, Tazocin is used as follows:

• Patients with renal failure or patients undergoing hemodialysis should receive an adjusted amount of the drug; this adjustment also applies to the frequency of administration of the drug;

The recommended dosage of the drug for adult and pediatric patients weighing over fifty kilograms with renal failure is as follows:

• if the creatine clearance is over forty ml per minute, the dosage of the drug does not need to be adjusted;
• with a creatine clearance of twenty to forty ml per minute, the amount of piperacillin is twelve grams, and the amount of tazobactam is one and a half grams per day; the drug is administered every eight hours in the amount of four grams of piperacillin and five hundred milligrams of tazobactam;
• with creatinine clearance less than twenty ml per minute, the amount of piperacillin per day is eight grams with a quantity of tazobactam of one gram; the active substances are administered every twelve hours in the amount of four grams of piperacillin and five hundred milligrams of tazobactam.

Patients undergoing hemodialysis should receive a maximum daily dose of eight grams of piperacillin and one gram of tazobactam. It should be taken into account that hemodialysis can remove thirty to fifty percent of piperacillin in four hours. In this case, it is necessary to prescribe one additional dose of two grams of piperacillin and two hundred and fifty grams of tazobactam after the end of each hemodialysis session.

The drug is prescribed with caution to pediatric patients aged two to twelve years with renal insufficiency, since the pharmacokinetic characteristics of piperacillin and tazobactam in children with renal impairment have not been studied. There are no data on the amounts of the drug in the simultaneous presence of renal dysfunction and neutropenia.

For pediatric patients aged two to twelve years with renal dysfunction, it is recommended to adjust the amount of the drug. It should be understood that the dose of Tazocin indicated for use is only a guideline for the required administration. Any patient in this group of patients should be constantly monitored by the attending staff in order to promptly identify symptoms of an overdose of the drug and take appropriate measures. Attention should be paid not only to the amount of medication for administration, but also to the interval between its use. The recommended doses of the drug and the time intervals between injections for pediatric patients weighing less than fifty kilograms are as follows:

• with a creatinine clearance of more than fifty ml per minute, the corresponding amount of Tazocin is one hundred twelve and a half milligrams per kilogram of the child's body weight (meaning one hundred milligrams of piperacillin and twelve and a half milligrams of tazobactam); the drug is to be administered every eight hours;
• if the clearance is less than fifty ml per minute, the appropriate amount of Tazocin is considered to be seventy-eight and three-quarter milligrams of the drug per kilogram of body weight (meaning seventy milligrams of piperacillin and eight and three-quarter milligrams of tazobactam); the drug is to be administered every eight hours.

There is no need to adjust the dosage of the drug if liver function is impaired.

In elderly patients, the dosage of the drug needs to be adjusted only in case of impaired renal function.

There are the following recommended procedures that should be used to prepare the medication solution:

• It is necessary to remind that Tazocin is used only for intravenous administration;
• the medicine must be dissolved in one of the solvents listed below;
• you need to pay attention to the volumes of the active components of the drug and the solvent;
• the bottle is rotated using circular movements until the contents of the bottle are dissolved - it is necessary to constantly rotate the bottle for five to ten minutes;
• The prepared solution is a colorless liquid or one with a light yellow tint.

The dosage of active components when preparing the solution is as follows:

• two grams of piperacillin and two hundred and fifty grams of tazobactam per ten milliliters of solvent;
• four grams of piperacillin and five hundred milligrams of tazobactan per twenty grams of solvent.

Among the solvents that are compatible with Tazocin, the following are recommended:

• 0.9% sodium chloride solution,
• sterile water for injection,
• five percent dextrose solution,
• Lactated Ringer's solution.

Once prepared, the solution can be diluted to the required volume to administer the drug intravenously. For example, dilution from fifty milliliters to one hundred and fifty milliliters with one of the following solvents is possible. Recommended use:

• 0.9% sodium chloride solution,
• sterile water for injection (at a maximum quantity of fifty milliliters),
• five percent dextrose solution,
• Lactated Ringer's solution.

The prepared solution should be used within twenty-four hours if the solution is stored at a temperature not exceeding twenty-five degrees Celsius. The solution should be used within forty-eight hours if it is stored at a temperature of two to eight degrees Celsius.

[ 24 ], [ 25 ], [ 26 ]

Use Tazocin during pregnancy

The use of Tazocin during pregnancy is as follows:

There is insufficient information on the combined use of piperacillin and tazobactam in Tazocin in women during pregnancy. This also applies to the separate use of these substances during this period.

The substances piperacillin and tazobactam are able to penetrate the placental barrier.

The drug may be prescribed to female patients during pregnancy only following strict indications and in case of vital necessity.

The drug Tazocin is prescribed during pregnancy only if there is an expected benefit to the mother, which is much more significant than the risk of a threat to the life and development of the fetus.

Piperacillin is able to enter breast milk in small concentrations. There is no data on tazobactam entering breast milk due to the lack of research into this problem.

Nursing women can use Tazobactam only if the effectiveness of the drug significantly exceeds the possible risks to the baby.

It is recommended to stop breastfeeding for the duration of taking Tazobactam.

Contraindications

Contraindications to the use of the drug Tazocin are as follows:

The presence of hypersensitivity to the active substances of the drug, including other penicillins, cephalosporins and carbapenems. The patient's medical history should contain data on the presence of allergic reactions in response to the use of penicillins, cephalosporins and carbapenems.

In the presence of any allergic reactions not only to drugs of the penicillin group, the drug Tazocin should be prescribed with caution.

There is no information on the safe use of the drug in patients under two years of age. Therefore, the drug Tazocin is not prescribed to patients under this age.

[ 19 ]

Side effects Tazocin

The practice of using the drug Tazocin has revealed the following side effects of the drug:

Manifestations of gastrointestinal disorders are symptoms of nausea, vomiting, diarrhea or constipation, stomatitis. Symptoms of dyspepsia are observed - difficult or painful digestion with the presence of pain in the epigastric region. Some patients experience pseudomembranous colitis - intestinal colic, which is characterized by paroxysmal abdominal pain and the separation of mucus with feces in large quantities.

Jaundice is observed. In some cases, increased activity of "liver" transaminases (AST and ALT) is observed as a temporary (transient) phenomenon. Symptoms of hyperbilirubinemia, increased activity of alkaline phosphatase, increased activity of gamma-glutamyl transferase, signs of hepatitis may appear.

The occurrence of allergic reactions - skin rash, itching, urticaria, erythema (reddening of the skin in a limited area). Sometimes signs of bullous dermatitis and erythema multiforme (including signs of Stevens-Johnson syndrome) are observed. In rare cases, manifestations of toxic epidermal necrolysis occur. The occurrence of anaphylactic (or anaphylactoid) reactions is possible, up to anaphylactic shock.

Fungal superinfections may occur.

The appearance of nervous system disorders is possible, which manifest themselves in the occurrence of headaches, insomnia, and convulsions.

In rare cases, symptoms of a disorder of the hematopoietic system may appear - anemia (a decrease in the level of hemoglobin in the blood), leukopenia (a decrease in the number of leukocytes in the blood serum), neutropenia (a decrease in the number of neutrophils in the blood), thrombocytopenia (a decrease in the number of platelets in the blood), and eosinophilia (an increase in the number of eosinophils in the blood) may appear.

Agranulocytosis may occur – a decrease in neutrophils and leukocytes in the blood, which provokes an increase in the patient's susceptibility to fungal and bacterial diseases. In some cases, symptoms of pancytopenia are observed – a decrease in the number of all blood cells – erythrocytes, thrombocytes, leukocytes.

Sometimes symptoms of hypoalbuminemia appear – a decrease in the amount of albumin in the blood plasma. Symptoms of hypoglycemia may be present – a decrease in the amount of glucose in the blood serum. Signs of hypoproteinemia appear, characterized by a low content of protein components in the blood plasma. Symptoms of hypokalemia may be present – a decrease in the concentration of potassium ions in the blood serum.

Some patients show signs of hypotension – low blood pressure. Phlebitis – inflammatory processes of the walls of blood vessels (veins) – may occur. Thrombophlebitis – inflammatory processes in the walls of blood vessels (veins) in combination with thrombosis – the formation of a blood clot that blocks the lumen of the vein – may also occur. A feeling of “flushes” of blood to the skin of the face may appear.

Sometimes bleeding, including purpura, nosebleeds are observed. The duration of bleeding may increase compared to the period before the use of the drug (i.e. the time for thromboplastin processes increases and the time of prothrombin processes increases).

Some patients may develop thrombocytosis – an increase in the number of platelets in the blood, which provokes the occurrence of thrombosis.

Patients prescribed Tazocin may have a false-positive Coombs test (a diagnostic test for autoimmune blood diseases).

The appearance of symptoms of arthralgia is observed - painful sensations in the joints, which are fleeting in nature.

Increased plasma creatinine levels are possible. Symptoms of interstitial nephritis and renal failure are observed.

Increased levels of urea in the blood plasma may occur.

In some cases, an increase in body temperature is observed, as well as the presence of local reactions - reddening of the skin, thickening of the skin and soft tissues in the area of drug administration.

[ 20 ], [ 21 ], [ 22 ], [ 23 ]

Overdose

An overdose of the drug Tazocin is manifested by the following symptoms:

• From the gastrointestinal tract, signs of nausea, vomiting, and diarrhea appear.
• From the nervous system, signs of neuromuscular excitability and convulsions occur.

Treatment of drug overdose depends on clinical manifestations. The patient is prescribed symptomatic therapy to relieve the consequences of improper medication intake.

To reduce high levels of piperacillin or tazobactam in the blood, hemodialysis (a method of extrarenal blood purification) may be prescribed.

[ 27 ], [ 28 ]

Interactions with other drugs

The following signs of interaction of the drug Tazocin with other drugs have been identified:

If Tazocin is prescribed for use in combination with probenecid, then T1/2 increases and renal clearance of both piperacillin and tazobactam decreases. At the same time, the maximum concentration level of these substances in the blood serum does not change.

The studies did not reveal any data on the interaction of Tazocin and Vancomycin, since no pharmacokinetic interaction between these drugs was detected.

Piperacillin, both when used separately and together with tazobactam, does not have a significant effect on the pharmacokinetic processes of Tobramycin. This applies to patients with intact renal function, as well as patients with some mild and moderate renal dysfunction. When using Tobramycin, the pharmacokinetic processes associated with piperacillin, tazobactam and their metabolites did not have significant changes.

When Tazocin and Vercuronium bromide are used in parallel, neuromuscular blockade may occur for a long period of time. This effect is observed with the combined use of piperacillin and other non-depolarizing muscle relaxants.

The combined use of Tazocin and Heparin, drugs with indirect anticoagulant action and other medications that affect the ability to clot blood (the blood coagulation system, which includes the functioning of platelets) should be done with caution. During the entire period of simultaneous treatment with these drugs, the level of blood coagulation and the state of the body system responsible for this function should be constantly monitored.

Piperacillin has the property of delaying the elimination of methotrexate from the body. As a result, during combination therapy with these substances, it is necessary to constantly monitor the level of methotrexate concentration in the blood plasma.

When using Tazocin, a false positive result may occur in the urine glucose test. This test uses a method that allows for the reduction of copper ions. Because of this fact, there are recommendations for glucose tests using enzymatic oxidation of glucose.

If Tazocin solutions and aminoglycosides are mixed, their inactivation may occur. As a result, these drugs should be administered separately. In cases where combined use is justified, Tazocin and aminoglycoside solutions should be prepared separately. Only a V-shaped catheter should be used when administering solutions of these drugs. If all of the above conditions are met, Tazocin may be administered to a patient using a V-shaped catheter only with the following aminoglycosides - amikacin and gentamicin. The dose of aminoglycosides is determined based on the patient's body weight, and the nature of the infection (serious or life-threatening) and renal function (creatinine clearance rate) are also important.

To use Tazocin, do not use a syringe or dropper that contains other medications. The exceptions are Gentamicin, Amikacin and the solvents specified in the previous paragraphs. This precaution is explained by the fact that there is no data on the compatibility of Tazocin and other medications.

If it is necessary to use Tazocin simultaneously with other drugs from the antibiotic group, these medications are administered to the patient in a strictly separate manner.

The drug Tazocin has the property of chemical instability, as a result of which this drug is not used simultaneously with solutions containing sodium bicarbonate.

The drug Tazocin is not recommended to be added to blood products or albumin hydrolysates.

[ 29 ], [ 30 ], [ 31 ], [ 32 ]

Storage conditions

Storage conditions for Tazocin are as follows:

The drug is stored at room temperature from fifteen to twenty degrees Celsius.

The medicine should be kept in a dry, dark place, out of direct sunlight.

Tazocin should be kept out of the reach of children.

[ 33 ]

Shelf life

The shelf life of the drug Tazocin is thirty-six months from the date of manufacture of the drug.

It is prohibited to use Tazocin for treatment after the expiration date of the drug indicated on the packaging.

[ 34 ], [ 35 ]